Sichuan Biokin Pharmaceutical

Historical price data

Sichuan Biokin Pharmaceutical's mission is to develop and commercialize high-quality, accessible biologic medicines for patients in China and worldwide. The company has achieved significant success by establishing itself as a dominant player in the Chinese biologics market, evidenced by its substantial market capitalization and integrated capabilities from discovery through commercialization. Its core strategy employs a dual-track approach: generating stable cash flow from biosimilars to fund the research and development of novel therapeutic antibodies in high-value therapeutic areas.

A fully integrated, proprietary biologics platform encompassing antibody discovery (hybridoma, phage display), protein engineering, cell line development, and large-scale GMP manufacturing for monoclonal antibodies and other protein therapeutics.

Faces intense competition from domestic integrated peers (e.g., Henlius, Innovent) in biosimilars and from both domestic innovators and global pharma giants in novel biologics. Its key advantages are vertical integration, commercial scale in China, and a balanced portfolio strategy.